Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 3 1

Status

Unknown 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2UNKNOWN 1OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 6Tumor-Agnostic 5Gynecologic 3Head & Neck 1

Conditions

Neoplasms 51Neoplasm Metastasis 18Carcinoma 9Neoplasms, Unknown Primary 8Carcinoma, Squamous Cell 7Adenocarcinoma 5

Interventions

Oxaliplatin 14Gemcitabine 13Fluorouracil 11Leucovorin 9Capecitabine 9pembrolizumab 7Docetaxel 7Irinotecan 6Paclitaxel 5zolbetuximab 4regorafenib 4Trastuzumab 4Radiotherapy 4Pemetrexed 4S 1 (combination) 3Ramucirumab 3Nivolumab 3Drug Therapy 3Cisplatin 3Bevacizumab 3vandetanib 2tislelizumab 2sargramostim 2lenvatinib 2icotinib 2camrelizumab 2bemarituzumab 2apatinib 2Phlebotomy 2Esophagectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Adenocarcinoma × Paclitaxel × Tumor-Agnostic × Clear all
NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

NCT00201734 2016-09-23

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
57 enrolled 11 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms, Neoplasms, Unknown Primary

NCT01253525 2014-06-18

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Eli Lilly and Company

Phase 1 Completed
6 enrolled 18 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡